Kristi McIntyre

6.5k citations

39 papers · 1.9k indexed · 1 hit paper · h-index 16

Cancer Research top 2%
- Breast Cancer Treatment Studies 18
Oncology top 2%
- Cancer Treatment and Pharmacology 21
- HER2/EGFR in Cancer Research 19
- PARP inhibition in cancer therapy 4
- Peptidase Inhibition and Analysis 3
Pulmonary and Respiratory Medicine top 5%
- Advanced Breast Cancer Therapies 9
Dermatology top 5%
Pathology and Forensic Medicine top 10%
Molecular Biology
- PI3K/AKT/mTOR signaling in cancer 4
Radiology, Nuclear Medicine and Imaging
- Monoclonal and Polyclonal Antibodies Research 3

Co-authors: Joyce O’Shaughnessy Svetislava J. Vukelja John Pippen Frankie A. Holmes Joanne L. Blum Lina Asmar Stephen E. Jones Kristi A. Boehm
Cited by: Cancer Research Oncology Pulmonary and Respiratory Medicine
Journals: Journal of Clinical Oncology (12 papers)SHILAP Revista de lepidopterología (1 paper)Cancer Research (4 papers)
Partner nations: United States Spain United Kingdom

In The Last Decade

Kristi McIntyre

38 papers receiving 1.8k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Kristi McIntyre

Since Specialization

Citations

This map shows the geographic impact of Kristi McIntyre's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kristi McIntyre with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kristi McIntyre more than expected).

Fields of papers citing papers by Kristi McIntyre

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kristi McIntyre. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kristi McIntyre. The network helps show where Kristi McIntyre may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Kristi McIntyre, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Kristi McIntyre Line = papers co-authored together Kristi McIntyre links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer European Journal of Cancer ·Sara M. Tolaney,Valentina Guarneri,Jae Hong Seo,Josefina Cruz,Miguel Henriques Abreu,Masato Takahashi,Carlos H. Barrios,Kristi McIntyre,Ran Wei,María del Mar Muñoz,Belén San Antonio,Astra M. Liepa,Miguel Martín,Stephen Johnston,Pirkko‐Liisa Kellokumpu‐Lehtinen,Nadia Harbeck	2024	10
2	93MO Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy for adjuvant HR+, HER2-, node-positive, high-risk, early breast cancer (EBC) ESMO Open ·Nadia Harbeck,Valentina Guarneri,Jae Hong Seo,Josefina Cruz Jurado,M.H. Abreu,M. Takahashi,Carlos H. Barrios,Kristi McIntyre,Ran Wei,Belén San Antonio,Astra M. Liepa,M. Martín Jiménez,SR Johnston,Sara M. Tolaney	2023	1
3	A Phase 2 Randomized Placebo-Controlled Adjuvant Trial of GI-4000, a Recombinant Yeast Expressing Mutated RAS Proteins in Patients with Resected Pancreas Cancer SHILAP Revista de lepidopterología ·Peter Muscarella,Tanios Bekaii‐Saab,Kristi McIntyre,Alexander S. Rosemurgy,Sharona Ross,Donald Richards,William E. Fisher,Patrick J. Flynn,Alicia Mattson,Claire Coeshott,Heinrich Röder,Joanna Roder,Frank E. Harrell,Allen Lee Cohn,Timothy C. Rodell,David Apelian,(unknown)	2021	17
4	Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer BMC Cancer ·Lee S. Schwartzberg,Kristi McIntyre,Sharon Wilks,Shannon Puhalla,Joyce O’Shaughnessy,Erhan Berrak,Yaohua He,Linda T. Vahdat	2019	5
5	Evaluation of Miracle Mouthwash plus Hydrocortisone Versus Prednisolone Mouth Rinses as Prophylaxis for Everolimus-Associated Stomatitis: A Randomized Phase II Study The Oncologist ·Vicky Jones,Kristi McIntyre,Devchand Paul,Sharon Wilks,Sharon M. Ondreyco,Scot Sedlacek,Anton Melnyk,Sanjay P. Oommen,Yunfei Wang,Susan Peck,Joyce O’Shaughnessy	2019	15
6	Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trialbreakdown → The Lancet Oncology ·Sibylle Loibl,Joyce O’Shaughnessy,Michael Untch,William M. Sikov,Hope S. Rugo,Mark D. McKee,Jens Huober,Mehra Golshan,Gϋnter von Minckwitz,David Maag,Danielle Sullivan,Norman Wolmark,Kristi McIntyre,José Ponce,Otto Metzger,Priya Rastogi,W. Fraser Symmans,Xuan Liu,Charles E. Geyer	2018	516
7	Five‐year results of a phase II trial of preoperative 5‐fluorouracil, epirubicin, cyclophosphamide followed by docetaxel with capecitabine (wTX) (with trastuzumab in HER2‐positive patients) for patients with stage II or III breast cancer Cancer Medicine ·Frankie A. Holmes,Beth A. Hellerstedt,John Pippen,Svetislava J. Vukelja,Rufus Collea,Darren M. Kocs,Joanne L. Blum,Kristi McIntyre,Minal Barve,Barry Don Brooks,Cynthia R. Osborne,Yunfei Wang,Lina Asmar,Joyce O’Shaughnessy	2018	2
8	Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor–Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial Journal of Clinical Oncology ·Ian Smith,Denise A. Yardley,Howard A. Burris,Richard de Boer,Dino Amadori,Kristi McIntyre,Bent Ejlertsen,Michael Gnant,W. Jonat,Kathleen I. Pritchard,Mitch Dowsett,Lowell L. Hart,Susan Poggio,Lisa Comarella,Hervé Salomon,Barbara D. Wamil,Joyce O’Shaughnessy	2017	68
9	Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine Clinical Cancer Research ·Joyce O’Shaughnessy,Hartmut Koeppen,Yuanyuan Xiao,Mark R. Lackner,Devchand Paul,Christopher Stokoe,John Pippen,Lea Krekow,Frankie A. Holmes,Svetislava J. Vukelja,Deborah Lindquist,Scot Sedlacek,Ragene Rivera,Robert J. Brooks,Kristi McIntyre,Carrie Brownstein,Silke Hoersch,Joanne L. Blum,Stephen E. Jones	2015	37
10	Impact of prior anthracycline or taxane use on eribulin effectiveness as first-line treatment for metastatic breast cancer: results from two phase 2, multicenter, single-arm studies SpringerPlus ·Joyce O’Shaughnessy,Kristi McIntyre,Lee S. Schwartzberg,Sharon Wilks,Shannon Puhalla,Erhan Berrak,James Song,Linda T. Vahdat	2015	14
11	Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin Combined With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive, Early-Stage Breast Cancer Clinical Breast Cancer ·John W. Smith,Svetislava J. Vukelja,Anthony Hoffman,Vicky Jones,Kristi McIntyre,Erhan Berrak,James Song,Joyce O’Shaughnessy	2015	13
12	Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer Breast Cancer Research and Treatment ·Kristi McIntyre,Joyce O’Shaughnessy,Lee S. Schwartzberg,Stefan Glück,Erhan Berrak,James Song,David L. Cox,Linda T. Vahdat	2014	48
13	Pathologic complete response after preoperative anti-HER2 therapy correlates with alterations in PTEN, FOXO, phosphorylated Stat5, and autophagy protein signaling BMC Research Notes ·Frankie A. Holmes,Virginia Espina,Lance A. Liotta,Yasir M. Nagarwala,Michael Danso,Kristi McIntyre,Cynthia R. Osborne,T Anderson,Lea Krekow,Joanne L. Blum,John Pippen,Allison Florance,Janine Mahoney,Joyce O’Shaughnessy	2013	50
14	CD30 expression in nonlymphomatous malignancies. Journal of Clinical Oncology ·Jeff P. Sharman,Jerome H. Goldschmidt,John M. Burke,Beth A. Hellerstedt,Kristi McIntyre,Christopher A. Yasenchak,Thomas E. Boyd,Robert L. Ruxer,Dipti Patel‐Donnelly,Fadi S. Braiteh,Andres Forero‐Torres,Michael A. Savin,Tina Albertson	2012	10
15	P5-13-03: Correlation of Clinical and Molecular Findings with Pathologic Response to Preoperative Lapatinib and Trastuzumab, Separately or in Combination, Prior to Neoadjuvant Chemotherapy for HER2 Positive Breast Cancer. Cancer Research ·FA Holmes,Virginia Espina,LA Liotta,Jae C. Chang,YX Nagarwala,Michael Danso,Kristi McIntyre,CR Osborne,LK Krekow,R. Gagnon,JM Mahoney,J. O’Shaughnessy	2011	4
16	Randomized, phase III study of adjuvant doxorubicin plus cyclophosphamide (AC) → docetaxel (T) with or without capecitabine (X) in high-risk early breast cancer: Exploratory Ki-67 analyses. Journal of Clinical Oncology ·John Pippen,Devchand Paul,Christopher Stokoe,Joanne L. Blum,Lea Krekow,F. A. Holmes,Deborah Lindquist,Scot Sedlacek,Ragene Rivera,Robert J. Brooks,S. Vukelja,Kristi McIntyre,Christine Lopez‐Diaz,J. O’Shaughnessy	2011	9
17	Results of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancer Breast Cancer Research and Treatment ·Nicholas J. Robert,Paul Conkling,Mark Allen O’Rourke,Paul R. Kuefler,Kristi McIntyre,Feng Zhan,Lina Asmar,Yanping Wang,Oluwatoyin Shonukan,Joyce O’Shaughnessy	2010	16
18	Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735 Journal of Clinical Oncology ·Stephen E. Jones,Frankie A. Holmes,Joyce O’Shaughnessy,Joanne L. Blum,Svetislava J. Vukelja,Kristi McIntyre,John Pippen,James H. Bordelon,Robert Kirby,John F. Sandbach,William Hyman,Donald Richards,Robert Mennel,Kristi A. Boehm,Wally Meyer,Lina Asmar,Daniel Mackey,Stefan Riedel,Hyman B. Muss,Michael A. Savin	2009	400
19	Results of a phase II open-label, nonrandomized trial of oral satraplatin in patients with metastatic breast cancer Breast Cancer Research and Treatment ·John W. Smith,Kristi McIntyre,Patrick V. Acevedo,Carlos A. Encarnacion,Karen L. Tedesco,Yunfei Wang,Lina Asmar,Joyce O’Shaughnessy	2009	14
20	Phase II Trial of Gemcitabine/Carboplatin (plus Trastuzumab in HER2-Positive Disease) in Patients with Metastatic Breast Cancer Clinical Breast Cancer ·David Loesch,Lina Asmar,Kristi McIntyre,Lisa L. Doane,Michael Monticelli,Devchand Paul,Svetislava J. Vukelja,Mauro Orlando,LaTrice G. Vaughn,Feng Zhan,Kristi A. Boehm,Joyce O’Shaughnessy	2008	24

About Kristi McIntyre

Kristi McIntyre is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine, having authored 39 papers that have together received 1.9k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (21 papers), HER2/EGFR in Cancer Research (19 papers), Breast Cancer Treatment Studies (18 papers), Advanced Breast Cancer Therapies (9 papers), PI3K/AKT/mTOR signaling in cancer (4 papers), PARP inhibition in cancer therapy (4 papers), Peptidase Inhibition and Analysis (3 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). The work is most often cited by research in Cancer Research (959 citations), Oncology (1.6k citations) and Pulmonary and Respiratory Medicine (405 citations). Kristi McIntyre has collaborated with scholars based in United States, Spain and United Kingdom. Frequent co-authors include Joyce O’Shaughnessy, Svetislava J. Vukelja, John Pippen, Frankie A. Holmes, Joanne L. Blum, Lina Asmar, Stephen E. Jones, Kristi A. Boehm, Donald Richards and Michael A. Savin. Their work appears in journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact